SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Novartis AG announced on Monday, Feb. 5, that it has acquired MorphoSys. The Basel, Switzerland-based pharmaceutical corporation agreed to buy the cancer drug developer for $2.9 billion or €2.7 billion.
As per Reuters, Novartis will offer shareholders €68 per share in cash. It also revealed its plan to take MorphoSys private once the deal is completed. Upon closing the transaction, which is expected within the first two quarters of this year, Novartis will now own pelabresib.
MorphoSys' Pelabresib Drug
This treatment has been described as one of the most promising cancer drugs. It is used to combat life-threatening forms of the intrusive disease. It was mentioned that pelabresib could be used for the treatment of rare bone marrow cancer called myelofibrosis and other types of lumpy lymphomas.
Through its purchase of MorphoSys, Novartis can bolster its oncology portfolio. This merger marks Novartis's first M&A deal this year. It was speculated earlier in January that it would buy Cytokinetics biotech firm, but the deal did not proceed.
Details of Transaction
Their respective Board unanimously approved the acquisition deal between Novartis and MorphoSys of Directors. While awaiting the final closing of the transaction, MorphoSys will continue to operate its business independently.
"We are excited about the opportunity of bringing pelabresib, a potential next-generation treatment combined with ruxolitinib, to people living with myelofibrosis, a rare and debilitating form of blood cancer," Novartis' president of development and chief medical officer, Shreeram Aradhye, M.D., said in a press release. "With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and portfolio in oncology, adding to our capabilities and expertise."
He added, "Building on our long-standing development partnership with MorphoSys, we look forward to continuing our work together to realize the full impact and value of their investigational medicines for patients with unmet needs."
Photo by: Novartis Media Library
